Paid Clinical Trials Wichita
Discover 163 paid clinical trials in Wichita, Kansas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
LY3556050A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT06074562
Conditions
Diabetic Peripheral Neuropathy
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
LY3556050
Placebo
Nivolumab, Ipilimumab, CabozantinibTesting the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03866382
Conditions
Bladder Adenocarcinoma
Bladder Clear Cell Adenocarcinoma
Bladder Mixed Adenocarcinoma
Bladder Neuroendocrine Carcinoma
Bladder Small Cell Neuroendocrine Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Bone Scan
Cabozantinib S-malate
Computed Tomography
Echocardiography Test
BLU-5937A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Sponsor:
Bellus Health Inc. - a GSK company
Location:
Code:
NCT05599191
Conditions
Refractory Chronic Cough
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
BLU-5937
Placebo
RGLS8429A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
Sponsor:
Regulus Therapeutics Inc.
Location:
Code:
NCT05521191
Conditions
Autosomal Dominant Polycystic Kidney Disease
ADPKD
Polycystic Kidney, Autosomal Dominant
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Interventions
RGLS8429
Placebo
CretostimogeneStudy of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Sponsor:
CG Oncology, Inc.
Location:
Code:
NCT04452591
Conditions
Non Muscle Invasive Bladder Cancer
High-grade Ta/ T1 Papillary Disease Bladder Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Cretostimogene Grenadenorepvec
n-dodecyl-B-D-maltoside
SaruparibSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Sponsor:
AstraZeneca
Location:
Code:
NCT06120491
Conditions
Metastatic Castration-Sensitive Prostate Cancer
Eligibility Criteria
Sex: Male
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Saruparib
Placebo
Abiraterone Acetate
Darolutamide
Enzalutamide
Zanubrutinib & Anti-CD20A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Sponsor:
BeiGene
Location:
Code:
NCT05100862
Conditions
Relapsed/Refractory Follicular Lymphoma
Marginal Zone Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Zanubrutinib
Rituximab
Lenalidomide
Obinutuzumab
Sacituzumab Tirumotecan & PembrolizumabSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06393374
Conditions
Triple-Negative Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
Sacituzumab tirumotecan
Capecitabine
GalcanezumabA Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT04616326
Conditions
Chronic Migraine
Eligibility Criteria
Sex: All
Age: 12 - 17
Healthy Volunteers: Not accepted
Interventions
Galcanezumab
Placebo
Glofitamab & Polatuzumab VedotinAn Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Sponsor:
Hoffmann-La Roche
Location:
Code:
NCT06047080
Conditions
Large B-Cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Glofitamab
Polatuzumab vedotin
Rituximab
Cyclophosphamide
Doxorubicin